A/Prof Nick Pavlakis underwent undergraduate medical training at the University of NSW and graduated in 1991. He also underwent general medical training and subsequent advanced training in Medical Oncology at Royal North Shore Hospital, completing FRACP in 1997. He then spent 3 years completing a PhD in new cancer drug development involving an Australian developed anti-angiogenic compound PI-88 (Progen Industries and ANU); and completed a Masters of Clinical Epidemiology through the University of Sydney. He has worked in private oncology practice since 1998 and has been a practice member of the Northern Cancer Institute since 2001. He is the President Elect of the Clinical Oncology Society for Australia (COSA), current Chair of the COSA Lung Cancer Group, and Regent for Australasia for the International Association for the Study of Lung Cancer (IASLC). He is an academic medical oncologist, having published journal manuscripts in his interest areas (lung cancer, mesothelioma, NETs, kidney cancer, gastric cancer, colorectal cancer and bisphosphonate therapy), is conducting ongoing collaborative clinical research with AGITG, ALTG, and ANZUP and translational research with the Bill Walsh Cancer Research Laboratories/Kolling Institute.
Abstracts this author is presenting: